Candel Therapeutics, Inc. Common Stock

CADL · Biotechnology · $830.2M
Powering up
CADL
$10.85
▼ −4.32%
09/18 O 11.28 H 11.38 L 10.78 C 10.85 ▼ −4.32%
Vol 3.0M RS 95
RS rating95
Now vs pivot (%)−4.49%
Tightening (ATR ratio)1.28×
Volume dry-up1.49×
Up/down volume, net-0.02
From 52-week high23%
squatfailed pokeplayed out
Previous breakout stopped out ▼ −9.97% in Apr
Powering up
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

The read

The base has run 6.2 weeks and fell 19% from its ceiling at its deepest. The pivot is $11.36, and the stock closed 4.5% below it. Its relative strength rating is 95.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap
  1. Earningstentativein 55d
    Quarterly earnings
    Nov 12, 2026
Flagged by the market sweep
GappedTape · 2026-09-12
-6.9%
Unusual volumeTape · 2026-09-12
4.8 sigma
A director or officer changedFiling · 2026-09-11
5.02
GappedTape · 2026-09-11
-6.9%

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means.

In the news
4 Prostate Cancer Drug Stocks to Watch During Awareness MonthZacks Investment Research · 4 days ago

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. Historical figures are backtests and are hypothetical.

What that means, in full
Candel Therapeutics, Inc. Common Stock (CADL) — The Tape